Production (Stage)
Inhibrx Biosciences, Inc.
INBX
$14.13
$0.211.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 100.00K | -- | 100.00K | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 100.00K | -- | 100.00K | 0.00 |
| Cost of Revenue | 1.26M | 33.37M | 38.89M | 67.63M | 4.19M |
| Gross Profit | -1.26M | -33.27M | -38.89M | -67.53M | -4.19M |
| SG&A Expenses | 6.02M | -51.40M | 7.90M | 93.37M | 9.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.90M | -18.03M | 46.80M | 161.00M | 73.83M |
| Operating Income | -42.90M | 18.13M | -46.80M | -160.90M | -73.83M |
| Income Before Tax | -43.31M | -47.87M | -43.86M | 1.86B | -78.71M |
| Income Tax Expenses | -- | 0.00 | -- | 2.00K | -- |
| Earnings from Continuing Operations | -43.31M | -47.87M | -43.86M | 1.86B | -78.71M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.31M | -47.87M | -43.86M | 1.86B | -78.71M |
| EBIT | -42.90M | 18.13M | -46.80M | -160.90M | -73.83M |
| EBITDA | -42.23M | 18.82M | -46.04M | -160.42M | -73.47M |
| EPS Basic | -2.80 | -3.09 | -2.84 | 127.10 | -5.77 |
| Normalized Basic EPS | -1.75 | 0.82 | -1.77 | -6.99 | -3.61 |
| EPS Diluted | -2.80 | -3.10 | -2.84 | 125.48 | -5.77 |
| Normalized Diluted EPS | -1.75 | 0.82 | -1.77 | -6.90 | -3.61 |
| Average Basic Shares Outstanding | 15.47M | 15.47M | 15.47M | 14.62M | 13.64M |
| Average Diluted Shares Outstanding | 15.47M | 15.47M | 15.47M | 14.81M | 13.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |